{"id":32513,"title":"Arecor Therapeutics PLC: A Rising Star in Diabetes and Obesity Innovations","publisher":"Stockmark.IT","author":"Stockmark.IT Website","published":"2024-05-18T10:10:50+00:00","modified":"2024-05-17T17:15:39+00:00","canonical_url":"https://stockmark.it/arecor-therapeutics-plc-a-rising-star-in-diabetes-and-obesity-innovations/","markdown_url":"https://stockmark.it/arecor-therapeutics-plc-a-rising-star-in-diabetes-and-obesity-innovations.md","json_url":"https://stockmark.it/arecor-therapeutics-plc-a-rising-star-in-diabetes-and-obesity-innovations.json","category":"Pharmaceutical","categories":["Pharmaceutical"],"featured_image":"https://i0.wp.com/stockmark.it/wp-content/uploads/arecor.jpg?fit=1200%2C800&quality=89&ssl=1","format":"news","language":"en-GB","content":"[Arecor Therapeutics PLC](https://arecor.com/), listed on AIM as AREC, has been making waves in the healthcare industry with its innovative approach to diabetes and obesity treatments. In a recent interview with Proactive Investor’s Stephen Gunnion, CEO Sarah Howell discussed the company’s impressive performance in 2023 and exciting plans for the future.\n\n**Strategic Growth and Global Partnerships**\n\nHowell highlighted the significant growth Arecor has experienced, particularly through the successful launch of products incorporating its revolutionary Arestat technology. These products are being distributed globally under a lucrative licensing agreement, resulting in the generation of substantial royalties. Additionally, the company has forged six new technology partnerships with major players in the pharma and biotech sectors, laying the groundwork for potential future licensing and market development opportunities.\n\n**Innovations in Diabetes and Obesity**\n\nArecor’s primary focus lies in the field of diabetes and obesity, with a particular emphasis on developing advanced solutions for patients. The company is on the cusp of releasing clinical results for its proprietary product, AT278, a highly concentrated rapid-acting insulin. This product is designed to enhance glucose control in individuals with type 2 diabetes and high BMIs while also supporting the next generation of insulin pump devices. Furthermore, Arecor’s subsidiary, Tetris Pharma, has experienced remarkable growth under new leadership, with sales of its lead product, glucagon, tripling to £2.9 million in 2023.\n\n**The Power of Strategic Partnerships**\n\nHowell underscored the importance of Arecor’s technology partnerships and licensing programs in driving innovation and growth. The company is currently engaged in three active license programs, all of which are progressing well with its partners. One standout collaboration is with industry giant Medtronic, aimed at developing a concentrated and stable insulin for intra-peritoneal delivery. This innovative solution has the potential to reduce hospital visits for patients struggling with brittle diabetes, showcasing Arecor’s commitment to improving patient outcomes through cutting-edge technology.\n\nIn conclusion, Arecor Therapeutics PLC is proving to be a rising star in the realm of diabetes and obesity innovations. With a keen focus on research and development, strategic partnerships, and a commitment to improving patient care, the company is well-positioned to continue driving positive change in the healthcare landscape."}